Global Retirement Partners’s Intellia Therapeutics NTLA Stock Holding History

Global Retirement Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08K	Buy	+64	New	+$896	﹤0.01%	4179
2025 Q4	$1.94K	Buy	216 +125	+137%	+$1.72K	﹤0.01%	3741
2025 Q3	$1.57K	Buy	91 +24	+36%	+$296	﹤0.01%	3390
2025 Q2	$628	Buy	+67	New	+$550	﹤0.01%	3546
2024 Q4	$8.96K	Buy	768 +664	+638%	+$10.4K	﹤0.01%	2435
2024 Q3	$2.14K	Hold	104	–	–	﹤0.01%	2913
2024 Q2	$2.33K	Buy	104 +41	+65%	+$976	﹤0.01%	2915
2024 Q1	$1.73K	Sell	63 -4	-6%	-$111	﹤0.01%	2799
2023 Q4	$1.79K	Buy	67 +1	+2%	+$29	﹤0.01%	2717
2023 Q3	$1.91K	Sell	66 -4	-6%	-$155	﹤0.01%	2557
2023 Q2	$2.85K	Hold	70	–	–	﹤0.01%	2410
2023 Q1	$2.7K	Buy	70 +7	+11%	+$275	﹤0.01%	2393
2022 Q4	$2.2K	Hold	63	–	–	﹤0.01%	2327
2022 Q3	$3K	Hold	63	–	–	﹤0.01%	2127
2022 Q2	$3K	Hold	63	–	–	﹤0.01%	2085
2022 Q1	$3K	Buy	+63	New	+$5.34K	﹤0.01%	2077

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Global Retirement Partners's NTLA Position: Q2 2026 in Review

Global Retirement Partners opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 64 shares worth $1.08K. The stake represents ﹤0.01% of the portfolio and ranks #4179 among its holdings. This is a return to the name: Global Retirement Partners previously reported a position in NTLA as recently as Q4 2025.

Global Retirement Partners first reported a position in NTLA in Q1 2022 and has held it in 16 quarters since. The position peaked at $8.96K in Q4 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Global Retirement Partners held 64 shares of Intellia Therapeutics worth $1.08K as of Q2 2026.
Intellia Therapeutics was a new Global Retirement Partners position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Global Retirement Partners's portfolio in Q2 2026, its #4179 holding.
Global Retirement Partners first reported a position in Intellia Therapeutics in Q1 2022 and has held it in 16 quarters since.
Global Retirement Partners's Intellia Therapeutics position peaked at $8.96K in Q4 2024.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Global Retirement Partners's 13F filing for Q2 2026, filed 6 Aug 2026.